We are located in Uppsala, the city of science.

Pharmetheus embraces all aspects of pharmacometric analyses, from data management  to Phase III filings.

Scientific rigor, timeliness and traceability are cornerstones of Pharmetheus’ services.

Pharmetheus offers consulting services focused on the application of pharmacometric approaches to support drug development decisions.

Pharmetheus offers pharmacometric services supporting drug development of compounds in all phases and in all therapeutic areas. Our overall aim is ultimately to improve patients’ lives. In support of our clients, we leverage on recent enhancements in model-based drug development methodology and tools to facilitate robust, tailored and timely decision making.

News

  • Mar 8, 2019
    Pharmetheus possesses a blend of expertise to enhance model informed drug development (MIDD) at the trial, compound and/or organization level. We are able to offer a range of MIDD related services tailored to your needs, such as: Presentations focused on MIDD awareness Workshops focused on MIDD implementation Workshops focused on MIDD application within particular therapeutic areas Scientific advice at the analysis, trial and compound levels Delivery of a range of MIDD components in a “fit for purpose” manner   For more information please contact Marie Sandström and info@pharmetheus.com.

  • Mar 8, 2019
    Pharmetheus is delighted to announce the appointment of Richard J Anziano as Chief Statistician. Rich was formerly Global Head of Statistics and Chief Statistician for Pfizer Inc. with responsibility for approximately 250 statisticians. In that role he led the quantitative assessment of late stage probabilities of technical and regulatory success through modeling and simulation for late-stage assets compared to industry/therapeutic area benchmarks. He was a long standing member of the cross PhRMA statistics group. He has over 25 years of drug development experience in Neuroscience, Pain, Cardiovascular, Infectious Disease, Rare Disease. He fostered a culture of collaboration and partnership across statisticians, clinical pharmacologists, and clinicians which enabled MIDD within Pfizer to effectively and efficiently support and inform development program strategies and decisions.

  • Mar 7, 2019
    We’ve moved! Pharmetheus has moved its main premises to a larger office complex based in the Uppsala Science Park. Beyond Uppsala, our physical presence stretches out through our office network (currently Stockholm and Basel), and home office network (currently Germany, Italy, The Netherlands, UK, USA, Sweden)

  • Feb 10, 2019
    Pharmetheus is pleased to announce the appointment of two new board members to our Board of Directors. Joining the Board are accomplished industry leaders Agneta Franksson and Fredrik Alpsten. Following the company’s recent growth and development, a reorganisation of the board was agreed to be in order. The new Board consists of Chairman Mats Karlsson, Martin Bergstrand, Elodie Plan, Agneta Franksson and Fredrik Alpsten.

  • Feb 4, 2019
    We are very pleased to announce the arrival of three new team members. We welcome Moustafa Ibrahim, Consultant; Georges Etté, Data Programmer; and Eric Sandström, Data Programmer to our growing Pharmetheus team. Moustafa has recently completed his PhD in pharmacometrics from Uppsala University, under the supervision of Professor Mats Karlsson and Associate Professor Maria Kjellsson. Georges is an experienced statistician and programmer who joins us from Novartis, and Eric has just concluded a Master thesis project over the last 4 months with us at Pharmetheus. Welcome and good luck to you all!

  • Jan 16, 2019
    The Pharmetheus team continues to grow. We would like to extend a warm welcome to three new employees who joined in January 2019. The three colleagues, Elin Matsson, Senior Consultant; Jurgen Langenhorst, Consultant and Peteris Prusis, Data Programmer add both extra capacity and additional capabilities to our high performing team. For more details on these colleagues, and the Pharmetheus Team as a whole please see our website which is about to undergo a revamp and refresh for 2019. Please inform us if there are elements you would like to see us add to the new website.

  • Jan 15, 2019
    We are happy to announce that Dr. Peter Milligan has joined Pharmetheus as the Chief Executive Officer (CEO) effective January 1st 2019. Peter was formerly Vice President, Global Head of Pharmacometrics and member of the Global Clinical Pharmacology Leadership Team at Pfizer. Our former CEO, Dr. Marie Sandström, who was instrumental in Peters’ recruitment process, becomes Chief Operating Officer (COO) with continued responsibility for Client Projects, and deputy CEO. The Pharmetheus team warmly welcomes Peter and wishes our CEO and COO great success in their new roles.

  • Jan 14, 2019
    We are delighted to inform you that Pharmetheus established an office in Basel, Switzerland, in October 2018. This is a noticeable development for Pharmetheus as the Basel site represents our first dedicated office space beyond  our current Swedish locations. The Basel site also has its first occupant. We welcomed Arnaud Gaby who joined in October 2018. Arnaud considerably strengthens our team of data programmers and the Pharmetheus team warmly welcomes him.

  • Oct 17, 2018
    Several of our colleagues have recently published a population PK/PD model for pegfilgrastim, a GCSF derivative alleviating chemotherapy side effects. The model was bidirectional and mechanism-based coupling pegfilgrastim concentrations to neutrophil kinetics. FREM was also performed to identify explanatory covariates. Here is a link to the article published in the AAPS Journal.

  • Oct 1, 2018
    Pharmetheus will be at ACoP, San Diego Oct 6-11, and we’d love to see you there! Stop by our booth, no. 10 along the wall with exits to the street, for more information about us or just a nice chat with some of our team members.

Menu